Today, there are a huge number of botulinum neurotoxins on the market of aesthetic medicine.
They are made by different companies, they come in different serotypes, however, they all have similar properties to block neuromuscular transmission, and as a result help fight wrinkles. Most of them are injected, but there are also developments of special toxins for topical use.
On estet-portal.com, read which neurotoxins will enter the world market in the near future, as well as what modern developments can become a real breakthrough in the beauty industry.
"New" botulinum toxins: what awaits the aesthetic medicine market
Every year more and more botulinum toxin preparations enter the world market. This allows you to create competition between companies, as a result of which the quality of products increases.
The FDA has approved the marketing of another botulinum toxin, Prabotulinumtoxin A, under the brand name Jeuveau. In fact, this is not a "new" a toxin, as is the case with most other toxins.
"New" Prabotulinumtoxin A is manufactured in South Korea by Daewoong Pharmaceuticals and has been available since 2014.
The next toxin likely to apply for FDA approval in 2020 will be from Revance Therapeutics, known as Daxi-daxibotulinumtoxin A. It was originally developed as a "local toxin", but after many years of research and investment, this idea was abandoned.
Another South Korean toxin expected to be approved in the second half of 2020 following phase III trials is letibotulinum toxin A, currently available as Botulax or Zentox.
There are several other toxins produced in different countries to meet local medical needs, but they have not made it to the wider aesthetic market. ChinaTox and Relatox appear to contain gelatin as excipients that have been reported to cause localized allergic reactions.
Local botulinum toxin: local effect of the toxin
The term «local toxin» is actually incorrect, it is actually a transdermal delivery technology that allows the transfer of the botulinum toxin molecule through the skin.
Revance was the leading company trying to develop their transdermal transfer system, but the company went out of business a few years later.
In 2016, Allergan announced the acquisition of Anterios Inc., which is also developing a next generation delivery system. With this acquisition, Allergan has acquired a potential development that allows local targeted delivery of neurotoxins through the skin without the need for injections.
Botox myths: debunking and warnings from a cosmetologist
Botulinum toxin: current news
Botulinum toxin is currently obtained from the fermentation of clostridium botulinum. After purification, the botulinum toxin subtype is obtained in the laboratory. Using recombinant gene technology, researchers have now modified the genes of E. coli so that these organisms will produce serotype A botulinum toxin.
At this stage, the possibility of using botulinum toxin for the treatment of hypertension is being studied.
Botulinum toxin type E has also recently gained interest, as it is reported to have a short duration of action. However, research on this serotype is still ongoing.
Read the latest articles in Telegram!
Share:
Add a comment